Sainuo Medical: The three products submitted by the company to the European Union CE certification registration application have not been rejected or failed, and the company will take legal measures in a timely manner for relevant false information and malicious reports

On September 8th, in response to the question of "the company's business in Europe has gone wrong" on the interactive platform, Sino Medical said that we have paid attention to the recent false information of various media such as stock bars and Snowball, and confirmed that the above information is misinformation, which is not in line with the actual situation of the company. In addition to the above information, some media maliciously exaggerated the company's receipt of administrative supervision measures, which caused the company's stock price to fluctuate sharply recently, causing certain troubles to the majority of investors. The company has intercepted and retained the above-mentioned relevant evidence, and has taken legal measures against relevant false information and malicious reports in a timely manner to effectively safeguard the interests of the majority of investors. The company's three neurointervention products (self-expanding stent, dense mesh stent, and thrombectomy stent) were submitted to the European Union CE certification registration application in the second half of 2024 and the first half of 2025 respectively. At present, they are all in the process of trial, and there is no case of being rejected or not passed. For the company's receipt of the decision on administrative supervision measures, we will explain again. The decision on administrative supervision measures is the final processing result of the Securities Regulatory Bureau. The company has not been investigated by the Securities Supervision Commission, nor will it be investigated by ST.